JWH-133

Drugbox
IUPAC_name = (6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H-dibenzo [b,d] pyran

---

width= 240
CAS_number= 259869-55-1
ATC_prefix=
ATC_suffix=
PubChem= 6918505
DrugBank=
C=22 | H=32 | O=1
molecular_weight = 312.489 g/mol
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status = Schedule I (US)
routes_of_administration=

JWH-133 is a potent selective CB₂ receptor agonist, with a Ki of 3.4nM and selectivity of around 200x for CB₂ over CB₁ receptors.

JWH-133, alongside WIN 55,212-2 and HU-210, is implicated in preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This antiinflamatory action is induced through agonist action at cannabinoid receptors, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.

Legal Status

JWH-133 is a Schedule I drug in the USA, despite being selective for the non-psychoactive CB₂ receptor and hence devoid of any psychoactive side effects or abuse potential.

External links

* [http://www.jneurosci.org/cgi/content/full/25/8/1904?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&fulltext=cannabinoid+alzheimer%27s&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT JNeurosci.org] Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation